CONCLUSION
With this study, we aimed to emphasize that the diagnosis, treatment and management of complications in lung cancer patients require more care than the normal population in the pandemic process. In the face of a multifactorial clinical condition such as the type of treatment, dose, duration of cytotoxic therapy they are taking, and stage of the disease, as clinicians, we should carry out the differential diagnosis process quickly by minimizing the risk of transmission. We need to accumulation of knowledge for these patients whose immunity has already been suppressed and cytokine responses have differentiated.